Bridgewest Group has acquired a sterile injectable manufacturing facility in Perth from Pfizer, enhancing its capabilities in the pharmaceutical sector.

Information on the Target

Bridgewest Group has successfully acquired a sterile injectable manufacturing facility located in Perth from Pfizer (Perth) Pty Ltd, a subsidiary of Pfizer, Inc. This facility is recognized for its compliance with current Good Manufacturing Practice (cGMP) standards and is equipped to produce a diverse range of high-quality sterile injectable drug products. With a sprawling area of 34,000 square meters, the facility employs over 400 staff members and operates nine production lines specializing in Oncology/High Potency, Blow-Fill-Seal, and multi-format vial streams. The acquisition, previously announced in a definitive agreement late last year, enhances Bridgewest's capabilities in pharmaceutical manufacturing.

The facility boasts an excellent regulatory history with approvals from significant health authorities including the FDA, TGA, and the EU, allowing it to distribute products to over 90 countries. Moving forward, the plant will operate as a Contract Development and Manufacturing Organization (CDMO), and will continue to manufacture drug products for Pfizer under a master services agreement, ensuring sustained quality and service for existing customers.

Industry Overview in Australia

The pharmaceutical industry in Australia is experiencing a remarkable transformation, driven by innovation and strong investment in research and development. The Australian government has been proactive in enhancing its role as a global leader in pha